Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Bertrand Routy(Centre Hospitalier de l’Université de Montréal), Saman Maleki Vareki(Ontario Institute for Cancer Research), Gianmarco Piccinno(University of Trento), Corentin Richard(Centre Georges François Leclerc), René Figueredo(Western University), Michael Silverman(Lakeridge Health), Seema Nair Parvathy(Western University), Kait F. Al(Western University), Réjean Lapointe(Montreal Neurological Institute and Hospital), Julian R. Marchesi(Imperial College London), Federica Pinto(University of Trento), Brendan A. Daisley(University of Guelph), Scott Ernst(Western University), Panteleimon G. Takis(Imperial College London), Benjamin H. Mullish(Imperial College Healthcare NHS Trust), Ian R. Watson(McGill University), LeeAnn Ramsay(McGill University), Arielle Elkrief(Centre Hospitalier de l’Université de Montréal), Wilson H. Miller(Jewish General Hospital), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal), Lisa Derosa(Institut Gustave Roussy), Mithunah Krishnamoorthy(Western University), John Lenehan(Western University), Laura Martínez-Gili(St Mary's Hospital), Nicola Segata(University of Trento), Jeremy P. Burton(Western University), Michal Punčochář(University of Trento), Khashayar Esfahani(McGill University), Federica Armanini(University of Trento), S. M. Mansour Haeryfar(Western University), Cecilia Hes(McGill University Health Centre), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Paméla Thébault(Centre Hospitalier de l’Université de Montréal), Diane Logan(Western University), Marina Ninkov(Western University), Karl Bélanger(Centre Hospitalier de l’Université de Montréal), Jamie Magrill(McGill University)
Cited by 446
Related Papers
Metagenomic biomarker discovery and explanation
|Genome biology|2011|16.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
A framework for human microbiome research
|Nature|2012|2.8k